Terlipressin Administration in Septic Shock Refractory to Catecholamines
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00793559 |
Recruitment Status
: Unknown
Verified November 2008 by Assaf-Harofeh Medical Center.
Recruitment status was: Not yet recruiting
First Posted
: November 19, 2008
Last Update Posted
: November 19, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Septic Shock | Drug: terlipressin | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II |
Study Start Date : | November 2008 |
Estimated Primary Completion Date : | July 2009 |
Estimated Study Completion Date : | July 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: terlipressin bolus
1 mg of terlipressin received one time only
|
Drug: terlipressin
1 mg of terlipressin one time only
Other Name: glypressin
|
Experimental: terlipressin drip |
Drug: terlipressin
1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
|
- CI, SVR,HR,BP, noradrenalin administration,renal function [ Time Frame: 6 mo ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- septic shock patients receiving above 0.5 mcg/kg NA
Exclusion Criteria:
- allergy to terlipressin, CHF, IHD, pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00793559
Contact: Tal Mann, Dr | 97257345789 | tal_mb@hotmail.com |
Israel | |
Asaf Harofeh MC | Not yet recruiting |
Zrifin, Israel, 70300 |
Study Director: | Tal Mann, Dr | Asaf Harofeh |
Responsible Party: | Dr Yuval Leonov, Assaf-Harofeh Medical Center |
ClinicalTrials.gov Identifier: | NCT00793559 History of Changes |
Other Study ID Numbers: |
161/08 |
First Posted: | November 19, 2008 Key Record Dates |
Last Update Posted: | November 19, 2008 |
Last Verified: | November 2008 |
Keywords provided by Assaf-Harofeh Medical Center:
septic shock refractory to catecholamines |
Additional relevant MeSH terms:
Shock Shock, Septic Pathologic Processes Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Terlipressin |
Lypressin Antihypertensive Agents Vasoconstrictor Agents Hemostatics Coagulants Antidiuretic Agents Natriuretic Agents Physiological Effects of Drugs |